Bevacizumab and endothelium dependent vasodilation - BVZach

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 24 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•1. Age 18-50 years old
•3. Results of serum glucose, lipids and creatinine should be within the laboratory's reference ranges.
•4. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.

•1. Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.
•2. History of or current abuse of drugs, alcohol or solvents.
•3. History of malignant disease.
•4. First degree relatives with a history of cancer before the age of 50
•5. First degree relatives with a history of premature cardiovascular disease before the age of 50
•6. Current use of medication.
•7. Hypertension ( systole >140mmHG, diastole >90mmHg)
•8. Diabetes mellitus
•9. Smoking
•10. Any clinically relevant abnormality on ECG.
•11. A history of thrombosis or first degree family members with a history of recurrent thrombosis
•12. Inability to understand the nature and extent of the trial and the procedures required.
•14. Previous participation in a study with bevacizumab.

发起方

niversitair Medisch Centrum Sint Radboud